HIPRA, a biotechnological company and member of Catalonia.health, and Elanco Animal Health have announced a strategic partnership to bring two vaccines against avian metapneumovirus (aMPV) to the United States poultry market. This collaboration addresses the need to provide new preventive tools against a highly contagious virus that primarily affects turkeys, but also broilers, laying hens and breeders.
Avian metapneumovirus causes respiratory diseases with a significant economic impact on poultry producers, and it is estimated that between 60% and 80% of commercial turkey flocks in the country may be affected by the virus. In this context, the introduction of vaccines represents a key solution to reduce the spread of the disease and the associated losses.
The vaccines to be introduced through this partnership are RESPIVAC® aMPV and HIPRAVIAR® TRT, both developed and manufactured by HIPRA. RESPIVAC® aMPV is a live attenuated vaccine based on subtype B that provides cross-protection against subtype A and can be administered in the hatchery, on the farm or during lay via spray or drinking water. Meanwhile, HIPRAVIAR® TRT is the only inactivated vaccine with the same subtype, origin and strain as the live vaccine, offering greater long-term protection.
According to company representatives, this collaboration has made it possible to overcome several challenges to bring the vaccines to the North American market with a consistent and effective supply. The combination of HIPRA’s global expertise in virus control and Elanco’s knowledge of the local market enables the delivery of solutions tailored to the needs of poultry producers in the United States and reinforces both companies’ commitment to international veterinary prevention.
Comments